New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:07 EDTAGN, VRX, MSAllergan: Executives from Morgan Stanley recently sent emails to management
Allergan (AGN) says executives from Morgan Stanley (MS), the investment bank understood to have recently been retained by Valeant (VRX), have sent emails directly to Allerganís management team that suggest they share the concerns of Allergan and third parties.
News For AGN;VRX;MS From The Last 14 Days
Check below for free stories on AGN;VRX;MS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 14, 2014
17:02 EDTAGNPershing Square gives quarterly update on stakes
Subscribe for More Information
14:28 EDTVRX, AGNAckman says Pershing, Valeant took no tender steps before buying Allergan shares
Bill Ackman made the statement to CNBC's Scott Wapner regarding his fund and Valeant's (VRX) pursuit of Allergan (AGN). Note that the Wall Street Journal reported earlier that the SEC is investigating Valeant and Pershing's pursuit of Allergan.
13:48 EDTAGN, VRXValeant, Pershing joint bid for Allergan being probed by SEC, WSJ says
Subscribe for More Information
13:22 EDTVRX, AGNValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
August 13, 2014
16:32 EDTAGNAllergan acquires LiRIS program from TARIS Biomedical
Allergan and TARIS Holdings announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedicalís lead program, LiRIS, which is currently in Phase 2 trials for the treatment of interstitial cystitis / bladder pain syndrome. Allergan paid $67.5M in cash upfront, subject to certain adjustments and holdbacks. Allergan has also agreed to pay up to an aggregate of $295M in development milestone payments and up to an aggregate of $225M in commercial milestone payments. Prior to the closing of this transaction, TARIS spun out certain assets, including pipeline programs and intellectual property related to TARISí platform technology, to a new company funded by TARIS shareholders.
06:19 EDTMSBanks pressing Federal Reserve to delay rule on investments, WSJ says
Banks are pushing U.S. policy makers for a delay of a rule that requires them to sell investments in private-equity and venture-capital funds, reports the Wall Street Journal. According to people familiar with the effort, bank officials, trade groups and lawmakers are lobbying the Federal Reserve to delay the rule for up to seven years that limits banks' investments. Reference Link
August 12, 2014
07:48 EDTMSBanks posted second-highest profit in 23 years in second quarter, WSJ says
Subscribe for More Information
August 11, 2014
17:36 EDTAGN, VRXValeant receives FTC second request under Hart-Scott-Rodino
Subscribe for More Information
12:52 EDTVRX, AGNAllergan receives second request from FTC regarding Valeant's proposal
Allergan (AGN) announced that it received a request for additional information under the Hart-Scott-Rodino Act from the U.S. Federal Trade Commission in connection with Valeant Pharmaceuticals International's (VRX) unsolicited acquisition proposal of Allergan. Allergan intends to respond fully in connection with the ongoing investigation. The Company noted that Second Request investigations typically take some time to conclude, and Allergan cannot predict how long this investigation will take or how it might otherwise develop. The company previously announced that Allerganís Board of Directors unanimously determined that Valeantís unsolicited exchange offer is grossly inadequate, substantially undervalues the company, creates significant risks and uncertainties for Allergan stockholders, and is not in the best interests of the company and its stockholders. Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the company and Latham & Watkins, Richards, Layton & Finger, P.A. and Wachtell, Lipton, Rosen & Katz are serving as legal counsel to the company.
12:42 EDTVRX, AGNValeant shareholder ValueAct sees no need to buy Allergan, Reuters says
Subscribe for More Information
12:27 EDTVRX, AGNValueAct says Valeant does not need to buy Allergan, Reuters says
Subscribe for More Information
07:22 EDTVRX, AGNJudge sets hearing date for Allergan suit vs. Valeant, Reuters reports
Subscribe for More Information
August 8, 2014
17:10 EDTVRX, AGNMarket finishes week up slightly as earnings offset by political events
Stocks finished the week fractionally higher than where they started as strong corporate earnings reports and better than expected economic data was weighed against concerns about geopolitical issues and negative M&A news. MACRO NEWS: A few ongoing geopolitical conflicts worried investors and weighed on shares. Russia unveiled sanctions against Western countries, banning the import of a wide range of food items from the U.S, the EU and a few allied countries in response to sanctions recently enacted against it from G7 nations... President Obama authorized the bombing of rebels in Iraq and Hamas and Israel failed to reach a permanent truce... An ISM services index, the U.S. trade deficit for June, and weekly jobless claims were all better than expected. Meanwhile, the increase in unit labor costs last quarter came in below the consensus outlook, perhaps easing fears that the Fed will need to raise interest rates sooner than expected. COMPANY NEWS: On the M&A front, two huge potential deals fell through as 21st Century Fox (FOX, FOXA) withdrew its offer to acquire Time Warner (TWX) and Sprint (S) reportedly decided to end its pursuit of a merger with peer T-Mobile (TMUS)... President Obama indicated that his administration would take unilateral steps in an effort to prevent companies from carrying out tax inversion acquisitions. Among the deals or possible transactions that involve inversion are Medtronic's (MDT) acquisition of Covidien (COV), Valeant's (VRX) proposed takeover of Allergan (AGN) and Mylan's (MYL) acquisition of Abbott's (ABT) developed markets branded generics pharmaceuticals business. Meanwhile, Walgreen's (WAG) stock tumbled after the U.S. company said it would not structure its takeover of European drugstore chain Alliance Boots as a tax inversion deal... 21st Century Fox, 3D printer maker Stratasys (SSYS), chip maker NVIDIA (NVDA), brewer Molson Coors (TAP), and luxury accessories maker Coach (COH) all rose following their earnings reports. Conversely, Target (TGT), luxury accessories maker Michael Kors (KORS) and Internet coupon provider Groupon (GRPN) fell following their results or guidance... Gannett (GCI) struck a deal to acquire the remaining 73% interest in Classified Ventures, whose primary asset is the online car shopping website Cars.com, for $1.8B from the other partners in the venture, which include McClatchy (MNI), Tribune Media (TRBAA), Graham Holdings (GHC) and A. H. Belo (AHC). Gannett also announced plans to spin-off its Publishing business, which includes USA Today, through a tax-free distribution to shareholders... McDonald's (MCD) stock was little changed after the company reported that its comparable store sales fell 2.5% in July, which was significantly worse than expected. Food quality issues weighed on the fast food company's sales in Asia and as a result of the China supplier issue, the company warned its previously issued global comparable sales forecast for 2014 is now at risk. INDEXES: The Dow finished the week up 0.35% to 16,553.93, the S&P 500 rose 0.32% to 1,931.59, and the Nasdaq gained 0.41% to 4,370.90.
10:58 EDTVRX, AGNAllergan rises after analyst sees compelling risk/reward, upgrades stock
Shares of drug maker Allergan (AGN) are rising after research firm Leerink Swann upgraded the stock in a note to investors today. WHAT'S NEW: After Allergan's stock fell recently, the shares' risk/reward ratio has become "increasingly positive" and is now compelling, Leerink analyst Seamus Fernandez wrote. Allergan's business has shown little if any weakness as a result of Valeant's (VRX) takeover bid for the company and Allergan's planned restructuring is overdue, the analyst contended. The weakness in Allergan's shares has been caused mainly by technical and arbitrage issues, according to Fernandez, who forecasts that the company can generate EPS of over $8.20 next year. Meanwhile, Valeant's bid will prevent Allergan's stock from dropping too far as long as it is on the table, Fernandez believes. Allergan has a number of other upcoming potential positive catalysts, including a potential $5B-$10B share repurchase initiative and data due to be released on August 12 on DARPin, the company's drug for wet age-related macular degeneration. A potential compelling acquisition by Allergan could also boost the stock, the analyst wrote. He upgraded the stock to Outperform from Market Perform and placed a $184 price target on the shares. PRICE ACTION: In mid-morning trading, Allergan rose $3.98, or 2.6%, to $155.67.
10:00 EDTAGNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Activision Blizzard (ATVI) upgraded to Buy from Neutral at Longbow... Allergan (AGN) upgraded to Outperform from Market Perform at Leerink... Andersons (ANDE) upgraded to Buy from Hold at Feltl... Arista Networks (ANET) upgraded to Buy from Neutral at Citigroup... Barrick Gold (ABX) upgraded to Conviction Buy from Buy at Goldman... Brinker (EAT) upgraded to Outperform from Market Perform at Raymond James... CF Industries (CF) upgraded to Buy from Hold at Feltl... CST Brands (CST) upgraded to Neutral from Underperform at Credit Suisse... Cimarex Energy (XEC) upgraded to Accumulate from Hold at KLR Group... Coca-Cola HBC (OCCH) upgraded to Buy from Hold at Deutsche Bank... Delek US (DK) upgraded to Outperform at Cowen... Fifth Street Finance (FSC) upgraded to Buy from Neutral at Guggenheim... Glimcher Realty Trust (GRT) upgraded to Buy from Neutral at BofA/Merrill... Goodrich Petroleum (GDP) upgraded to Strong Buy from Outperform at Raymond James... Monster Beverage (MNST) upgraded to Neutral from Underperform at Longbow... NIC Inc. (EGOV) upgraded to Outperform from Market Perform at Barrington... NVIDIA (NVDA) upgraded at Needham... POZEN (POZN) upgraded to Buy from Hold at Ascendiant... Power Solutions (PSIX) upgraded to Accumulate from Neutral at Global Hunter... Primoris (PRIM) upgraded to Buy from Hold at BB&T... Sierra Bancorp (BSRR) upgraded to Outperform from Market Perform at Raymond James... Sonus Networks (SONS) upgraded to Outperform from Market Perform at Barrington... Stone Energy (SGY) upgraded to Buy from Accumulate at KLR Group... Tornier (TRNX) upgraded at BMO Capital... Tyson Foods (TSN) upgraded to Buy from Hold at BB&T... WGL Holdings (WGL) upgraded to Buy from Hold at Brean Capital.
07:18 EDTMSRegulators direct banks to steer mortgage aid to hard-hit areas, FT says
Subscribe for More Information
07:01 EDTVRX, AGNHarvard professor says Treasury can reduce inversion incentives, NY Times says
Subscribe for More Information
06:16 EDTVRX, AGNAllergan upgraded to Outperform from Market Perform at Leerink
Leerink upgraded its rating on Allergan (AGN) shares to Outperform citing a compelling risk/reward profile following the recent pullback in shares. The firm believes Valeant's (VRX) takeover attempt is having little if any impact on Allergan's business. Leerink has a $184 price target for Allergan shares, which closed yesterday down $5.18 to $151.92.
05:50 EDTVRXStocks with implied volatility movement; TWX VRX
Stocks with implied volatility movement; Time Warner (TWX) 30, Valeant (VRX) 49 according to iVolatility.
August 7, 2014
06:42 EDTAGN, VRXObama to look to limit inversion deals, Politico says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use